← All companies

Eli Lilly

5 reports

Research on this company

J.P. Morgan

J.P. Morgan: Eli Lilly weight-loss drug tracker: Zepbound accounts for over half of incremental prescriptions as oral market expansion and uptake diverge

JPMorgan believes oral weight-loss drugs primarily attract new patients and have yet to materially displace Zepbound; Medicare coverage has also driven Kwikpen prescriptions sharply above their June level. However, Kwikpen prescriptions fell in the latest week, while the initial uptake of Lilly’s oral drug Foundayo remains weaker than that of oral Wegovy.